前列腺癌中前列腺酸性磷酸酶和前列腺特异性抗原免疫化学检测的评估

An evaluation of the immunochemical measurement of prostatic acid phosphatase and prostatic specific antigen in carcinoma of the prostate.

作者信息

Siddall J K, Cooper E H, Newling D W, Robinson M R, Whelan P

出版信息

Eur Urol. 1986;12(2):123-30. doi: 10.1159/000472596.

PMID:2420600

Abstract

Serum prostatic specific antigen (PSA) and prostatic acid phosphatase (PAP) were evaluated with double monoclonal radioimmunoassays. In 250 patients with prostatic cancer the normal limits were as follows: PSA 0.1-2.7 ng/ml, and PAP 1.09 +/- 0.45 ng/ml (mean +/- SD). In 91 untreated patients with non-metastatic tumours, 42.8% had PSA greater than 10 ng/ml and 18.6% had PAP greater than 2 ng/ml. In 60 untreated patients with metastatic disease PSA was greater than 10 ng/ml in 91.7%; PAP was greater than 2 ng/ml in 65%. In prolonged remission PSA was generally less than 5 ng/ml and PAP less than 2 ng/ml. Longitudinal studies of 2-4 years showed the independence of these markers and a higher correlation of changes in the PSA level and clinical status than given by parallel PAP measurements. In non-metastatic disease, PSA greater than 10 ng/ml at presentation, with or without a coincidentally raised PAP, carried an increased risk of progression within 2 years.

摘要

采用双单克隆放射免疫分析法对血清前列腺特异性抗原（PSA）和前列腺酸性磷酸酶（PAP）进行评估。在250例前列腺癌患者中，正常范围如下：PSA为0.1 - 2.7 ng/ml，PAP为1.09±0.45 ng/ml（均值±标准差）。在91例未经治疗的非转移性肿瘤患者中，42.8%的患者PSA大于10 ng/ml，18.6%的患者PAP大于2 ng/ml。在60例未经治疗的转移性疾病患者中，91.7%的患者PSA大于10 ng/ml；65%的患者PAP大于2 ng/ml。在长期缓解期，PSA一般小于5 ng/ml，PAP小于2 ng/ml。2至4年的纵向研究表明，这些标志物相互独立，与并行的PAP测量相比，PSA水平变化与临床状态的相关性更高。在非转移性疾病中，初诊时PSA大于10 ng/ml，无论PAP是否同时升高，2年内进展风险均增加。